The forgotten majority: Unfinished business in cardiovascular risk reduction

Journal of the American College of Cardiology

Volumn 46, Issue 7, 2005, Pages 1225-1228

  Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET; EVALUATION; EXERCISE; FOLLOW UP; HEALTH STATUS; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCANDINAVIA;

CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; TIME FACTORS;

EID: 27744522317     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.07.006     Document Type: Review

References (21)

1. Centers for Disease Control, National Center for Health Statistics. Available at: http://www.cdc.gov/nccdphp/burdenbook2002/. Accessed July 18, 2005.
2. American Heart Association 2001 Heart and Stroke Statistical Update 2000 American Heart Association Dallas, TX
3. C.J. Murray, A.D. Lopez Regional patterns of disability-free life expectancy and disability-adjusted life expectancy global Burden of Disease Study Lancet 349 1997 1347 1352
4. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
5. F.M. Sacks, M.A. Pfeffer, L.A. Moye Cholesterol And Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
6. J.R. Downs, M. Clearfield, S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial Lancet 360 2002 7 22
9. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
10. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial JAMA 291 2004 1071 1080
11. M.H. Frick, O. Elo, K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
12. Helsinki heart study: a controlled coronary prevention trial. Design and baseline findings Eur Heart J 8 Suppl I 1987 1 43
13. H.B. Rubins, S.J. Robins, D. Collins Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial study group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
14. H. Bloomfield Rubins, J. Davenport, V. Babikian Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol the Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation 103 2001 2828 2833
15. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women Circulation 86 1992 839 848
16. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
17. G. Steiner The DAIS Project Group The Diabetes Atherosclerosis Intervention Study (DAIS) a study conducted in cooperation with the World Health Organization Diabetologia 39 1996 1655 1661
18. G. Steiner, D. Stewart, J.D. Hosking Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes Am J Cardiol 84 1999 1004 1010
19. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
20. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
21. S.W. Altmann, H.R. Davis Jr., L.J. Zhu Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201 1204